Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Joanna B. Eldredge & Alex C. Spyropoulos. (2018) Direct oral anticoagulants in the treatment of pulmonary embolism. Current Medical Research and Opinion 34:1, pages 131-140.
Read now
Read now
Benilde Cosmi. (2016) An update on the pharmaceutical management of thrombosis. Expert Opinion on Pharmacotherapy 17:16, pages 2149-2164.
Read now
Read now
Mark Pluym & Gregory Howell. (2014) Management of Hemorrhage with the Target-Specific Oral Anticoagulants. Hospital Practice 42:3, pages 75-83.
Read now
Read now
Articles from other publishers (29)
Ze Li, Siyu Yang, Zixin Hua, Yanxia Lu & Xingang Li. (2023) Population pharmacokinetics of rivaroxaban in Chinese deep vein thrombosis patients and the exposure simulation for dosing recommendation. Naunyn-Schmiedeberg's Archives of Pharmacology.
Crossref
Crossref
Srikanth Reddy Surukonti, M S Surendrababu, Naresh Kumar Katari & Rajender Reddy Yerla. (2023) Investigating Betrixaban Maleate drug degradation profiles, isolation and characterization of unknown degradation products by mass-triggered preparative HPLC, HRMS, and NMR.. Journal of Pharmaceutical and Biomedical Analysis, pages 115643.
Crossref
Crossref
Daan Sondag, Stijn Verhoeven, Dennis W. P. M. Löwik, Mark van Geffen, Cornelis van't Veer, Waander L. van Heerde, Thomas J. Boltje & Floris P. J. T. Rutjes. (2023) Activity Sensing of Coagulation and Fibrinolytic Proteases. Chemistry – A European Journal 29:18.
Crossref
Crossref
Min Mao, Yan Sheng Shan, Xiao Meng Wang, Pei Yu Guo, Fei Guo, Ling Feng Pan, Zi Dan Wang, Zhi Ping Xu, Qi Hui Zhou & Liang Shan. (2022) Improved Anticoagulant Effect of Layered Double Hydroxide‐Heparin Nanocomposites on the Microcirculation of Septic Rats. Advanced Therapeutics 6:3.
Crossref
Crossref
Zhi-Li Zhang, Changming Chen, Si-Ying Qu, Qiulan Ding & Qin Xu. (2022) Unexpected Dynamic Binding May Rescue the Binding Affinity of Rivaroxaban in a Mutant of Coagulation Factor X. Frontiers in Molecular Biosciences 9.
Crossref
Crossref
Ju-Hsuan Yang, Hsin-Ming Chen, Ying-Shiung Kuo & Chun-Pin Chiang. (2020) Management of patients taking antithrombotic drugs before dental surgery. Journal of Dental Sciences 15:2, pages 222-224.
Crossref
Crossref
Si‐Ying Qu, Qin Xu, Wenman Wu, Fang Li, Cheng‐Dong Li, Ran Huang, Qiulan Ding & Dong‐Qing Wei. (2019) An unexpected dynamic binding mode between coagulation factor X and Rivaroxaban reveals importance of flexibility in drug binding. Chemical Biology & Drug Design 94:3, pages 1664-1671.
Crossref
Crossref
. 2019. Demystifying Drug Dosing in Renal Dysfunction. Demystifying Drug Dosing in Renal Dysfunction
101
151
.
Eberhard Wieland & Maria Shipkova. (2019) Pharmacokinetic and Pharmacodynamic Drug Monitoring of Direct-Acting Oral Anticoagulants: Where Do We Stand?. Therapeutic Drug Monitoring 41:2, pages 180-191.
Crossref
Crossref
Sophie Testa, Claudia Dellanoce, Oriana Paoletti, E. Cancellieri, Rossella Morandini, Maurizio Tala, Silvia Zambelli & Cristina Legnani. (2019) Edoxaban plasma levels in patients with non-valvular atrial fibrillation: Inter and intra-individual variability, correlation with coagulation screening test and renal function. Thrombosis Research 175, pages 61-67.
Crossref
Crossref
Danial E. Baker. (2017) Formulary Drug Review: Betrixaban. Hospital Pharmacy 53:1, pages 29-37.
Crossref
Crossref
Kunihiko Nagakari, Mari Emmi & Toshiaki Iba. (2016) Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect. Clinical and Applied Thrombosis/Hemostasis 23:6, pages 677-684.
Crossref
Crossref
Teruhiro Sakaguchi, Hiroyuki Osanai, Yosuke Murase, Hideki Ishii, Yoshihito Nakashima, Hiroshi Asano, Susumu Suzuki, Mikito Takefuji, Yasuya Inden, Kazuyoshi Sakai, Toyoaki Murohara & Masayoshi Ajioka. (2017) Monitoring of anti-Xa activity and factors related to bleeding events: A study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban. Journal of Cardiology 70:3, pages 244-249.
Crossref
Crossref
Jean Amiral & Jerard Seghatchian. (2017) Monitoring of anticoagulant therapy in cancer patients with thrombosis and the usefulness of blood activation markers. Transfusion and Apheresis Science 56:3, pages 279-286.
Crossref
Crossref
Annemarie Bluecher, Sascha Meyer dos Santos, Nerea Ferreirós, Sandra Labocha, Isabel Maria Rodrigues Meyer dos Santos, Bettina Picard-Willems, Sebastian Harder & Oliver C. Singer. (2017) Microfluidic coagulation assay for monitoring anticoagulant therapy in acute stroke patients. Thrombosis and Haemostasis 117:03, pages 519-528.
Crossref
Crossref
Jean Amiral, Claire Dunois, Cédric Amiral & Jerard Seghatchian. (2016) Anti-Xa bioassays for the laboratory measurement of direct Factor Xa inhibitors in plasma, in selected patients. Transfusion and Apheresis Science 55:2, pages 249-261.
Crossref
Crossref
Carlos E. Pompilio, Paolo Pelosi & Melina G. Castro. (2016) The Bariatric Patient in the Intensive Care Unit: Pitfalls and Management. Current Atherosclerosis Reports 18:9.
Crossref
Crossref
Maiko Yuri, Yoko Tabe, Koji Tsuchiya, Ryo Sadatsuki, Jun Aoki, Takashi Horii, Toshiaki Iba & Akimichi Ohsaka. (2015) Evaluation of Factor Xa-Specific Chromogenic Substrate Assays and the Determination of Pharmacokinetics of Fondaparinux. Clinical and Applied Thrombosis/Hemostasis 22:5, pages 453-458.
Crossref
Crossref
James A. Reiffel, Jeffrey I. Weitz, Paul Reilly, Edvardas Kaminskas, Troy Sarich, Philip Sager & Jonathan Seltzer. (2016) NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. American Heart Journal 177, pages 74-86.
Crossref
Crossref
Toshiaki Iba, Mari Emmi, Makoto Hiki, Masataka Nagayama, Koichiro Aihara, Yoko Tabe, Maiko Yuri & Akimichi Ohsaka. (2016) Comparison of prothrombin time tests used in the monitoring of edoxaban and their evaluation as indicators of the reversal effect. International Journal of Hematology 103:6, pages 665-672.
Crossref
Crossref
David Faraoni, Charles Marc Samama, Marco Ranucci, Wulf Dietrich & Jerrold H. Levy. (2014) Perioperative Management of Patients Receiving New Oral Anticoagulants. Clinics in Laboratory Medicine 34:3, pages 637-654.
Crossref
Crossref
Job Harenberg, Sandra Krämer, Shanshan Du, Shabnam Zolfaghari, Astrid Schulze, Roland Krämer, Christel Weiss, Martin Wehling & Gregory Y. H. Lip. (2014) Measurement of rivaroxaban and apixaban in serum samples of patients. European Journal of Clinical Investigation 44:8, pages 743-752.
Crossref
Crossref
J. Harenberg, S. Du, C. Weiss, R. Krämer, D. Hoppensteadt & J. Walenga. (2014) Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis 12:5, pages 801-804.
Crossref
Crossref
Rohan Willis, Eon Nigel Harris & Silvia Pierangeli. (2014) The future of treatment for antiphospholipid syndrome. International Journal of Clinical Rheumatology 9:1, pages 41-57.
Crossref
Crossref
Masashi Kanemoto, Hiroko Kuhara, Toru Ueda, Takahiro Shinohara, Takamasa Oda, Fumiaki Nakao, Toshiaki Kamei, Yasuhiro Ikeda & Takashi Fujii. (2014) Association of Apixaban Therapy and Prothrombin Time in Patients With Atrial Fibrillation. Circulation Journal 78:11, pages 2651-2656.
Crossref
Crossref
Shinya Suzuki, Takayuki Otsuka, Koichi Sagara, Hiroto Kano, Shunsuke Matsuno, Yuko Kato, Hideaki Takai, Tokuhisa Uejima, Yuji Oikawa, Kazuyuki Nagashima, Hajime Kirigaya, Junji Yajima, Hitoshi Sawada, Tadanori Aizawa & Takeshi Yamashita. (2014) Rivaroxaban in Clinical Practice for Atrial Fibrillation With Special Reference to Prothrombin Time. Circulation Journal 78:3, pages 763-766.
Crossref
Crossref
Anne-Sophie Dincq, Sarah Lessire, Jonathan Douxfils, Jean-Michel Dogné, Maximilien Gourdin & François Mullier. (2014) Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting. BioMed Research International 2014, pages 1-16.
Crossref
Crossref
Kenneth A. Bauer. (2013) Pros and cons of new oral anticoagulants. Hematology 2013:1, pages 464-470.
Crossref
Crossref
E. Fiaccadori, U. Maggiore & G. Regolisti. (2013) Balancing thromboembolic risk against vitamin K antagonist-related bleeding and accelerated calcification: is fondaparinux the Holy Grail for end-stage renal disease patients with atrial fibrillation?. Nephrology Dialysis Transplantation 28:12, pages 2923-2928.
Crossref
Crossref